In an interview with Biopharma Reporter, Mainz Biomed CEO Guido Baechler explains how his company’s stool test for colorectal cancer compares with well known, multicancer blood tests like Galleri. Early detection blood tests such as Grail’s Galleri typically involve isolating DNA from the blood and deploying machine-learning algorithms to scan…
YonaLink, a pioneering company in digital healthcare, is set to change that. In an in-depth interview with senior editor, Liza Laws, Gav Martell, co-founder of Yonalink, shared insights into his journey, the company’s groundbreaking technology, and the promising future of clinical trials. The genesis of Yonalink Gav Martell’s path to…
Also known as precision medicine, this kind of individualized treatment is designed specifically for the patient and has revolutionized cancer therapies in recent years. These treatments also have massive potential for reproductive health and, by extension, the developmental and reproductive toxicology (DART) field, which studies the toxicological effects on reproductive…
These efforts are driven by the need for transparency, compliance, and sustainability in response to pressures from stakeholders, including investors, regulators, and consumers. In this piece, industry experts share their insights on the actions being taken and the challenges faced in this important area. Insights from industry leaders: Nic Nunn-Faron,…
This groundbreaking approval is expected to transform the market for patients suffering from moderate to severe exacerbations, particularly those with limited treatment options. Asiyah Nawab, a Pharma Analyst at GlobalData, provides her expert insights on the approval and its implications. “Ohtuvayre, a first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor, has great…
Check out five upcoming AI players attracting investor attention for their potential to speed up drug discovery. Drug discovery is a laborious undertaking that traditionally involves lots of trial-and-error drug screening to arrive at a potential candidate for further development. For this reason, the process can take several years and…
This collaboration aims to unite experts from various fields to explore how emerging protein science can address the challenges in drug discovery. ELRIG UK, known for its commitment to delivering high-quality scientific conferences and networking events, focuses on innovative research that can transform drug discovery. TPS, an international scholarly society…
YonaLink, a pioneering company in digital healthcare, is set to change that. In an in-depth interview with senior editor, Liza Laws, Gav Martell, co-founder of YonaLink, shared insights into his journey, the company’s groundbreaking technology, and the promising future of clinical trials. The genesis of YonaLink Gav Martell’s path to…
This expansion, one of the largest in the company’s history, aims to enhance the production of injectable treatments for obesity and chronic diseases. This investment will create 1.4 million square feet of production space, doubling the footprint of Novo Nordisk’s existing facilities in North Carolina. The new facility will generate…
Ginny brings a wealth of knowledge and experience to the table from her diverse background in nursing, law, and regulatory policy. The conversation delved into the intricacies of global regulatory practices and the importance of collaboration in the industry. Liza Laws (LL): Thanks for joining me, Ginny. Could you start by…